-
LEO Pharma Presents Late-Breaking Results on Temtokibart for Atopic Dermatitis at EADV
18 Sep 2025 17:11 GMT
… Annual Meeting in Paris, France, LEO Pharma presented two late-breaking abstracts … advantages in specificity and safety. LEO Pharma has obtained a worldwide exclusive … , Science, Search & Innovation at LEO Pharma.
References
1. Weidinger S, et …
-
#EADV25: Leo Pharma details mid-stage win for IL-22 targeting antibody in atopic dermatitis
17 Sep 2025 14:19 GMT
-
Baricitinib Response Deepens Over Time in Alopecia Areata, With Brett King, MD, PhD
20 Sep 2025 12:47 GMT
… and Company, Incyte, Janssen Pharmaceuticals, LEO Pharma, Merck, Otsuka/Visterra, Pfizer …
-
<![CDATA[Significance of Cardiovascular Data on Upadacitinib for Atopic Dermatitis, With Christopher Bunick, MD, PhD]]>
20 Sep 2025 12:30 GMT
… an investigator for AbbVie, Incyte, LEO Pharma and Pfizer.
References
Bunick C …
-
FDA approves Opzelura cream for pediatric atopic dermatitis
20 Sep 2025 00:34 GMT
… , Galderma, Incyte, Johnson & Johnson, Leo Pharma, Eli Lilly, Pfizer, Primus Pharmaceuticals … , KP Away, L’Oreal, LearnSkin, LEO Pharma, Level Ex, Menlo Therapeutics, Micreos …
-
<![CDATA[Current Treatment Landscape for Moderate to Severe Atopic Dermatitis, With Raj Chovatiya, MD, PhD]]>
19 Sep 2025 18:58 GMT
… Bio, Galderma, Genentech, GSK, Incyte, LEO Pharma, L'Oréal, Nektar Therapeutics …
-
DELTA TEEN Trial Demonstrates Superiority of Delgocitinib Cream in Adolescents With Chronic Hand Eczema
19 Sep 2025 18:21 GMT
… science, search, and innovation at LEO Pharma, in the news release. … 16 weeks.2
References
LEO Pharma presents late-breaking phase … ;20250918307792/en/LEO-Pharma-Presents-Late-Breaking-Phase-3 … ) in adults. News release. LEO Pharma Inc. July 23, 2025. …
-
<![CDATA[Cardiovascular Risk and Upadacitinib Treatment for Atopic Dermatitis, With Christopher Bunick, MD, PhD]]>
19 Sep 2025 18:58 GMT
… an investigator for AbbVie, Incyte, LEO Pharma and Pfizer.
References
Bunick C …
-
Topical Therapies Remain Central in Atopic Dermatitis Treatment Strategies
19 Sep 2025 16:19 GMT
… ; Sanofi and Regeneron), tralokinumab (Adbry; LEO Pharma), and lebrikizumab (Eblgyss; Eli Lilly …
-
EADV 2025: Day 2 Recap
19 Sep 2025 01:53 GMT
… inflammatory pathways for effective relief.
LEO Pharma unveils promising phase 2b trial …